Evidence map›Paper›PMID 27838951›Full record

ArticleLeukemia & lymphoma2017

Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.

David A Bond, Ying Huang, Amy S Ruppert, Alison R Walker, Emily K Dotson, Julianna Roddy, Kristie A Blum, Beth A Christian

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

David A Bonda Department of Internal Medicine , The Ohio State University , Columbus , OH , USA.
Ying Huangb Division of Hematology , The Ohio State University , Columbus , OH , USA.
Amy S Ruppertb Division of Hematology , The Ohio State University , Columbus , OH , USA.
Alison R Walkerb Division of Hematology , The Ohio State University , Columbus , OH , USA.
Emily K Dotsonc Department of Pharmacy , The Ohio State University , Columbus , OH , USA.
Julianna Roddyc Department of Pharmacy , The Ohio State University , Columbus , OH , USA.
Kristie A Blumb Division of Hematology , The Ohio State University , Columbus , OH , USA.
Beth A Christianb Division of Hematology , The Ohio State University , Columbus , OH , USA.
The Ohio State University · US

Funding

Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib eraK24CA201524 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A · 2015 to 2019
$886k
NCI NIH HHS K24 CA201524
6 · The paper itself

Abstract

The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outcome. The starting dosage ranged from 50 to 90 mg/m

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideFemaleHumansKaplan-Meier EstimateLymphoma, Mantle-CellMaleMiddle AgedNeoplasm StagingOdds RatioProportional Hazards ModelsRetrospective StudiesRituximabBendamustine HydrochlorideRituximabBendamustineimmunotherapeutic approacheslymphoma and Hodgkin disease

Identifiers

PMID27838951
PMCPMC5499523
OpenAlexW2551542239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.